{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:23:05Z","timestamp":1789939385045,"version":"4.0.1"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"12","funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-062"],"award-info":[{"award-number":["2023-I2M-C&T-B-062"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0533201"],"award-info":[{"award-number":["2024ZD0533201"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0743_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate quantification of aldosterone is critical for screening and diagnosing primary aldosteronism (PA). Current competitive chemiluminescence immunoassays (cCLIA) overestimate plasma aldosterone concentration (PAC) compared to liquid chromatography-tandem mass spectrometry (LC-MS\/MS). However, LC-MS\/MS is technically demanding and time-consuming, limiting its widespread clinical utility. Therefore, a novel two-step sandwich chemiluminescence immunoassay (sCLIA) for accurate quantification of PAC was systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0743_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Precision, trueness, linear range, and maximum dilution factor of the new immunoassay were comprehensively validated. In a multicenter study involving 2,696 samples from seven Chinese centers, PAC measurements were performed in parallel using sCLIA, cCLIA, and LC-MS\/MS. The study specifically focused on evaluating the assay\u2019s performance at low aldosterone concentrations and in patients with chronic kidney disease (CKD), investigating potential interference from renal impairment by comparing the consistency between immunoassays and LC-MS\/MS results across different CKD stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0743_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sCLIA exhibited excellent analytical performance for PAC measurement, with intra-assay imprecision &lt;4.64\u202f% and bias &lt;5.71\u202f% against certificated reference materials. The assay exhibited a wide reportable range (30\u2013100,000\u202fng\/L) with a limit of quantification at 30\u202fng\/L and dilution capability \u226550-fold. Compared to cCLIA, sCLIA showed superior agreement with LC-MS\/MS, particularly at low PAC concentrations (&lt;110\u202fng\/L) and in subjects with reduced renal function (eGFR&lt;60\u202fmL\/min\/1.73\u202fm\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0743_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This novel sCLIA method exhibited excellent analytical performance, combining the practical advantages of immunoassays with LC-MS\/MS accuracy, thereby offering an ideal solution for large-scale primary aldosteronism screening in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0743","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:55:53Z","timestamp":1755845753000},"page":"2477-2484","source":"Crossref","is-referenced-by-count":4,"title":["An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7105-8563","authenticated-orcid":false,"given":"Kaijuan","family":"Wang","sequence":"first","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Cong","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangwei","family":"Gao","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Gao","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Shi","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, National Clinical Research Center for Cardiovascular Diseases , Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College\/National Center for Cardiovascular Diseases , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025110712102427589_j_cclm-2025-0743_ref_001","doi-asserted-by":"crossref","unstructured":"Mancia, G, Kreutz, R, Brunstr\u00f6m, M, Burnier, M, Grassi, G, Januszewicz, A, et al.. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J\u00a0Hypertens 2023;41:1874\u20132071.","DOI":"10.1097\/HJH.0000000000003480"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_002","doi-asserted-by":"crossref","unstructured":"Monticone, S, D\u2019Ascenzo, F, Moretti, C, Williams, TA, Veglio, F, Gaita, F, et al.. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41\u201350.","DOI":"10.1016\/S2213-8587(17)30319-4"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_003","doi-asserted-by":"crossref","unstructured":"Reincke, M, Bancos, I, Mulatero, P, Scholl, UI, Stowasser, M, Williams, TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021;9:876\u201392.","DOI":"10.1016\/S2213-8587(21)00210-2"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_004","doi-asserted-by":"crossref","unstructured":"Mulatero, P, Monticone, S, Deinum, J, Amar, L, Prejbisz, A, Zennaro, M-C, et al.. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J\u00a0Hypertens 2020;38:1919\u201328.","DOI":"10.1097\/HJH.0000000000002510"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_005","doi-asserted-by":"crossref","unstructured":"Funder, JW, Carey, RM, Mantero, F, Murad, MH, Reincke, M, Shibata, H, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab 2016;101:1889\u2013916.","DOI":"10.1210\/jc.2015-4061"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_006","doi-asserted-by":"crossref","unstructured":"Zhou, W, Deng, Y, Ma, W, Zhao, H, Wang, K, Zhang, Q, et al.. Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China. Clin Chem Lab Med 2024;62:2233\u201341.","DOI":"10.1515\/cclm-2024-0373"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_007","doi-asserted-by":"crossref","unstructured":"Zeng, Q, Li, J, Yang, Y, He, Y, Song, Y, Hu, J, et al.. Comparison of a chemiluminescence immunoassay with LC-MS\/MS in the determination of the plasma aldosterone concentration in patients with impaired renal function. Steroids 2025;213:109540.","DOI":"10.1016\/j.steroids.2024.109540"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_008","doi-asserted-by":"crossref","unstructured":"Lam, L, Chiu, WW, Davidson, JS. Overestimation of aldosterone by immunoassay in renal impairment. Clin Chem 2016;62:890\u20131.","DOI":"10.1373\/clinchem.2016.255737"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_009","doi-asserted-by":"crossref","unstructured":"Handelsman, DJ, Wartofsky, L. Requirement for mass spectrometry sex steroid assays in the journal of clinical endocrinology and metabolism. J\u00a0Clin Endocrinol Metab 2013;98:3971\u20133.","DOI":"10.1210\/jc.2013-3375"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_010","doi-asserted-by":"crossref","unstructured":"Constantinescu, G, Bidlingmaier, M, Gruber, M, Peitzsch, M, Poitz, DM, Van Herwaarden, AE, et al.. Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clin Chim Acta 2020;507:98\u2013103.","DOI":"10.1016\/j.cca.2020.04.019"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_011","doi-asserted-by":"crossref","unstructured":"Yin, Y, Ma, C, Yu, S, Liu, W, Wang, D, You, T, et al.. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone. Clin Chem Lab Med 2019;58:95\u2013102.","DOI":"10.1515\/cclm-2019-0706"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_012","doi-asserted-by":"crossref","unstructured":"Naruse, M, Katabami, T, Shibata, H, Sone, M, Takahashi, K, Tanabe, A, et al.. Japan endocrine society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 2022;69:327\u201359.","DOI":"10.1507\/endocrj.EJ21-0508"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_013","doi-asserted-by":"crossref","unstructured":"McEvoy, JW, McCarthy, CP, Bruno, RM, Brouwers, S, Canavan, MD, Ceconi, C, et al.. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912\u20134018.","DOI":"10.1093\/ehjcvp\/pvae084"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_014","doi-asserted-by":"crossref","unstructured":"Deng, L, Xiong, Z, Li, H, Lei, X, Cheng, L. Analytical validation and investigation on reference intervals of aldosterone and renin in Chinese Han population by using fully automated chemiluminescence immunoassays. Clin Biochem 2018;56:89\u201394.","DOI":"10.1016\/j.clinbiochem.2018.04.016"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_015","doi-asserted-by":"crossref","unstructured":"Fortunato, A, Prontera, C, Masotti, S, Franzini, M, Marchetti, C, Giovannini, S, et al.. State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the cardiovascular biomarkers study group of the Italian section of European society of ligand assay (ELAS) and societ\u00e0 italiana di biochimica clinica (SIBIOC). Clin Chim Acta Int J Clin Chem 2015;444:106\u201312.","DOI":"10.1016\/j.cca.2015.01.028"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_016","doi-asserted-by":"crossref","unstructured":"Ozeki, Y, Tanimura, Y, Nagai, S, Nomura, T, Kinoshita, M, Shibuta, K, et al.. Development of a new chemiluminescent enzyme immunoassay using a two-step sandwich method for measuring aldosterone concentrations. Diagnostics 2021;11:433.","DOI":"10.3390\/diagnostics11030433"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_017","doi-asserted-by":"crossref","unstructured":"Eisenhofer, G, Kurlbaum, M, Peitzsch, M, Constantinescu, G, Remde, H, Schulze, M, et al.. The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy. J\u00a0Clin Endocrinol Metab 2022;107:e2027\u201336.","DOI":"10.1210\/clinem\/dgab924"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_018","doi-asserted-by":"crossref","unstructured":"Wu, V-C, Yang, S-Y, Lin, J-W, Cheng, B-W, Kuo, C-C, Tsai, C-T, et al.. Kidney impairment in primary aldosteronism. Clin Chim Acta 2011;412:1319\u201325.","DOI":"10.1016\/j.cca.2011.02.018"},{"key":"2025110712102427589_j_cclm-2025-0743_ref_019","doi-asserted-by":"crossref","unstructured":"Kawashima, A, Sone, M, Inagaki, N, Takeda, Y, Itoh, H, Kurihara, I, et al.. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur J Endocrinol 2019;181:339\u201350.","DOI":"10.1530\/EJE-19-0047"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0743\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:11:31Z","timestamp":1762517491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0743\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["10.1515\/cclm-2025-0743"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0743","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}